PURPOSE: We sought to identify racial differences among histological subtypes of renal cell carcinoma (RCC) between black and non-black patients in an equal-access health care system. MATERIALS AND METHODS: We established a multi-institutional, prospective database of patients undergoing partial or radical nephrectomy between January 1, 2000 and Sept 31, 2009. For the purposes of this study, data captured included age at diagnosis, race, tumor size, presence of lymphovascular invasion, presence of capsular invasion, margin status, and tumor histology. RESULTS: 204 kidney tumors were identified (Table-1). Of these, 117 (57.4%) were in black patients and 87 (42.6%) were in non-black patients. Age at surgery ranged from 37 to 87 with a median of 62. Tumor size ranged from 1.0 to 22.0 cm with a median of 5.0 cm. Overall, tumors were composed of clear cell RCC in 97 cases (47.5%), papillary RCC in 65 cases (31.9%), chromophobe RCC in 13 cases (6.4%), collecting duct/medullary RCC in 2 cases (1.0%), RCC with multiple histological subtypes in 8 cases (3.9%), malignant tumors of other origin in 6 cases (2.9%), and benign histology in 13 cases (6.4%). Among black patients, papillary RCC was seen in 56 cases (47.9%), compared to 9 cases (10.3%) among non-black patients (p < 0.001) (Table-2). Clear cell RCC was present in 38 (32.5%) of black patients and in 59 (67.8%) of non-blacks (p < 0.001). CONCLUSIONS: In our study, papillary RCC had a much higher occurrence among black patients compared to non-black patients. This is the first study to document such a great racial disparity among RCC subtypes.
PURPOSE: We sought to identify racial differences among histological subtypes of renal cell carcinoma (RCC) between black and non-black patients in an equal-access health care system. MATERIALS AND METHODS: We established a multi-institutional, prospective database of patients undergoing partial or radical nephrectomy between January 1, 2000 and Sept 31, 2009. For the purposes of this study, data captured included age at diagnosis, race, tumor size, presence of lymphovascular invasion, presence of capsular invasion, margin status, and tumor histology. RESULTS: 204 kidney tumors were identified (Table-1). Of these, 117 (57.4%) were in black patients and 87 (42.6%) were in non-black patients. Age at surgery ranged from 37 to 87 with a median of 62. Tumor size ranged from 1.0 to 22.0 cm with a median of 5.0 cm. Overall, tumors were composed of clear cell RCC in 97 cases (47.5%), papillary RCC in 65 cases (31.9%), chromophobe RCC in 13 cases (6.4%), collecting duct/medullary RCC in 2 cases (1.0%), RCC with multiple histological subtypes in 8 cases (3.9%), malignant tumors of other origin in 6 cases (2.9%), and benign histology in 13 cases (6.4%). Among black patients, papillary RCC was seen in 56 cases (47.9%), compared to 9 cases (10.3%) among non-black patients (p < 0.001) (Table-2). Clear cell RCC was present in 38 (32.5%) of black patients and in 59 (67.8%) of non-blacks (p < 0.001). CONCLUSIONS: In our study, papillary RCC had a much higher occurrence among black patients compared to non-black patients. This is the first study to document such a great racial disparity among RCC subtypes.
Authors: Joshua Sterling; Zorimar Rivera-Núñez; Hiren V Patel; Nicholas J Farber; Sinae Kim; Kushan D Radadia; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer Journal: Clin Genitourin Cancer Date: 2020-03-20 Impact factor: 2.872
Authors: Catherine L Callahan; Jonathan N Hofmann; Douglas A Corley; Wei K Zhao; Brian Shuch; Wong-Ho Chow; Mark P Purdue Journal: Cancer Epidemiol Date: 2018-07-18 Impact factor: 2.984
Authors: Onder Kara; Hiury S Andrade; Homayoun Zargar; Oktay Akca; Matthew J Maurice; Peter A Caputo; Daniel Ramirez; Ercan Malkoc; Charles S Modlin; Jihad H Kaouk Journal: J Robot Surg Date: 2016-02-09
Authors: Sachin K Deshmukh; Shafquat Azim; Aamir Ahmad; Haseeb Zubair; Nikhil Tyagi; Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Rodney P Rocconi; Ajay P Singh Journal: Am J Cancer Res Date: 2017-01-01 Impact factor: 6.166
Authors: Mark P Purdue; Lee E Moore; Maria J Merino; Paolo Boffetta; Joanne S Colt; Kendra L Schwartz; Vladimir Bencko; Faith G Davis; Barry I Graubard; Vladimir Janout; Julie J Ruterbusch; Jennifer Beebe-Dimmer; Michele L Cote; Brian Shuch; Dana Mates; Jonathan N Hofmann; Lenka Foretova; Nathaniel Rothman; Neonilia Szeszenia-Dabrowska; Vsevolod Matveev; Sholom Wacholder; David Zaridze; W Marston Linehan; Paul Brennan; Wong-Ho Chow Journal: Int J Cancer Date: 2013-01-15 Impact factor: 7.396
Authors: Andrew F Olshan; Tzy-Mey Kuo; Anne-Marie Meyer; Matthew E Nielsen; Mark P Purdue; W Kimryn Rathmell Journal: Cancer Med Date: 2013-08-06 Impact factor: 4.452
Authors: Abiodun Mafolasire; Xiaopan Yao; Cayce Nawaf; Alfredo Suarez-Sarmiento; Wong-Ho Chow; Wei Zhao; Douglas Corley; Jonathan N Hofmann; Mark Purdue; Adebowale J Adeniran; Brian Shuch Journal: Cancer Med Date: 2016-05-26 Impact factor: 4.452